South Korean AI‑driven protein discovery firm Galux signed a research agreement with Boehringer Ingelheim to explore AI‑guided, purpose‑specific protein molecule design. Galux will validate whether de novo AI approaches can produce proteins with defined structural and translational properties that conventional discovery struggles to achieve. The collaboration targets proof‑of‑concept cases to evaluate feasibility and translational value, building on Galux’s internal de novo antibody milestones and Boehringer’s biologics expertise.